Literature DB >> 17223913

JAK2 (V617F) mutation in healthy individuals.

Francesco Passamonti, Elisa Rumi, Daniela Pietra, Mario Lazzarino, Mario Cazzola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17223913     DOI： 10.1111/j.1365-2141.2006.06483.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  12 in total

1.  The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Randall J Olsen; Cherie H Dunphy; Dennis P O'Malley; Lawrence Rice; April A Ewton; Chung-Che Chang
Journal:  J Hematop       Date:  2008-08-28       Impact factor: 0.196

2.  Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.

Authors:  David A Hinds; Kimberly E Barnholt; Ruben A Mesa; Amy K Kiefer; Chuong B Do; Nicholas Eriksson; Joanna L Mountain; Uta Francke; Joyce Y Tung; Huong Marie Nguyen; Haiyu Zhang; Linda Gojenola; James L Zehnder; Jason Gotlib
Journal:  Blood       Date:  2016-06-30       Impact factor: 22.113

3.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

4.  The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels.

Authors:  Giuseppe Tagariello; Rosanna Di Gaetano; Roberto Sartori; Daniela Zanotto; Donata Belvini; Paolo Radossi; Renzo Risato; Giovanni Roveroni; Roberta Salviato; Cristina Tassinari; Nunzio Toffano
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

5.  Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm.

Authors:  Fani Kalala; Antigoni Mamara; Maria Ioannou; Matthaios Speletas
Journal:  Hematol Rep       Date:  2012-06-29

Review 6.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

7.  The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Authors:  Margherita Perricone; Nicola Polverelli; Giovanni Martinelli; Lucia Catani; Emanuela Ottaviani; Elisa Zuffa; Eugenia Franchini; Arbana Dizdari; Dorian Forte; Elena Sabattini; Michele Cavo; Nicola Vianelli; Francesca Palandri
Journal:  Oncotarget       Date:  2017-06-06

8.  Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Authors:  Margherita Perricone; Francesca Palandri; Emanuela Ottaviani; Mario Angelini; Laura Bagli; Enrica Bellesia; Meris Donati; Donato Gemmati; Patrizia Zucchini; Stefania Mancini; Valentina Marchica; Serena Trubini; Giovanna De Matteis; Silvia Di Zacomo; Mosè Favarato; Annamaria Fioroni; Caterina Bolzonella; Giorgia Maccari; Filippo Navaglia; Daniela Gatti; Luisa Toffolatti; Linda Orlandi; Vèronique Laloux; Marco Manfrini; Piero Galieni; Barbara Giannini; Alessia Tieghi; Sara Barulli; Maria Luisa Serino; Monica Maccaferri; Anna Rita Scortechini; Nicola Giuliani; Daniele Vallisa; Massimiliano Bonifacio; Patrizia Accorsi; Cristina Salbe; Vinicio Fazio; Milena Gusella; Eleonora Toffoletti; Marzia Salvucci; Mirija Svaldi; Filippo Gherlinzoni; Francesca Cassavia; Francesco Orsini; Giovanni Martinelli
Journal:  Oncotarget       Date:  2017-05-16

Review 9.  Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Christoph Bock; Tracy I George; Stephen J Galli; Jason Gotlib; Torsten Haferlach; Gregor Hoermann; Olivier Hermine; Ulrich Jäger; Lukas Kenner; Hans Kreipe; Ravindra Majeti; Dean D Metcalfe; Alberto Orfao; Andreas Reiter; Wolfgang R Sperr; Philipp B Staber; Karl Sotlar; Charles Schiffer; Giulio Superti-Furga; Hans-Peter Horny
Journal:  EBioMedicine       Date:  2017-11-26       Impact factor: 8.143

10.  Reactive Thrombocytosis Associated with Acute Myocardial Infarction following STEMI with Percutaneous Coronary Intervention.

Authors:  Nat Dumrongmongcolgul; Charoen Mankongpaisarnrung; Grerk Sutamtewagul; Nattamol Hosiriluck; Timothy Chen; Alexander Trujillo; Nicholas Dcunha; Kenneth Nugent; Leigh Ann Jenkins
Journal:  Case Rep Cardiol       Date:  2013-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.